ARA-290: what the published research shows
ARA-290 is a non-hematopoietic erythropoietin analogue studied in diabetic macular oedema, sarcoidosis small fibre neuropathy, prediabetes and type 2 diabetes, and cognitive processing. This page summarises the registere
ARA-290 (also written ARA 290) is a synthetic peptide developed as a non-hematopoietic erythropoietin analogue. It is designed to act at the innate repair receptor without stimulating red blood cell production, which is the property that limits repeated use of erythropoietin itself. The published and registered research on ARA-290 spans diabetic macular oedema, sarcoidosis-associated small fibre neuropathy, prediabetes and type 2 diabetes, and cognitive and neural processing of emotion in healthy volunteers. The evidence base is a mixture of completed and ongoing clinical trials, with the mechanistic rationale drawn from the innate repair receptor pathway.
The work centres on the innate repair receptor, a receptor complex through which ARA-290 is reported to produce anti-apoptotic and anti-inflammatory activity in a range of cells, tissues and organs [2]. That receptor-level activity is the common thread across the clinical programmes described below. Where a finding comes from an animal model or an in vitro system rather than a human trial, it is labelled as such in the sections that follow.
Research Studies
ARA-290 and diabetic macular oedema in type 1 and type 2 diabetes
A prospective, open-label, interventional, single-centre, investigator-led phase II trial has been registered to examine the effect of ARA 290 on diabetic macular oedema in patients with type 1 or type 2 diabetes [1]. The primary objective is to determine whether ARA 290 administered at a daily dose of 4 mg subcutaneously for 12 weeks to patients with diabetes mellitus and diabetic macular oedema has a beneficial effect on the mean change in best corrected visual acuity (BCVA) from baseline to week 12 [1]. The trial is registered as ARA 290-DMO [1].
| Parameter | Detail |
|---|---|
| Population | Type 1 or type 2 diabetes with diabetic macular oedema [1] |
| Design | Prospective, open-label, interventional, single-centre, investigator-led phase II [1] |
| Dose and route | 4 mg subcutaneously daily [1] |
| Duration | 12 weeks [1] |
| Primary endpoint | Mean change in best corrected visual acuity (BCVA) from baseline to week 12 [1] |
ARA-290 and corneal nerve fibre density in sarcoidosis small fibre neuropathy
A separate study was designed to determine whether ARA 290 is effective in the treatment of the neuropathic symptoms of sarcoidosis [2]. The stated rationale is that brief interaction of ARA 290 with the innate repair receptor results in anti-apoptotic and anti-inflammatory activities across many cells, tissues and organs, activating repair mechanisms and accelerating healing, including the nerve damage that can be associated with sarcoidosis [2]. In that study, subjects with sarcoidosis and symptoms of small fibre neuropathy were to receive ARA 290 or placebo by subcutaneous injection daily for 28 days, with safety monitoring alongside assessment of symptoms [2].
| Parameter | Detail |
|---|---|
| Population | Sarcoidosis with symptoms of small fibre neuropathy [2] |
| Comparison | ARA 290 versus placebo [2] |
| Dose and route | Subcutaneous injection daily [2] |
| Duration | 28 days [2] |
| Outcomes | Safety monitoring and assessment of neuropathic symptoms [2] |
ARA-290 and glycaemic control in prediabetes and type 2 diabetes
A further registered study was set up to determine whether ARA 290, described as a non-hematopoietic erythropoietin analogue, exerts beneficial effects on blood glucose levels and insulin secretion in persons with prediabetes (impaired glucose tolerance or impaired fasting glucose) or drug-naive type 2 diabetes [3]. The same study was designed to evaluate effects of ARA 290 on insulin sensitivity and serum levels of inflammatory agents such as cytokines, with safety monitored through haematology, kidney and liver function parameters and lipid levels [3].
ARA-290 and cognitive and neural processing of emotion in healthy volunteers
Studies on erythropoietin indicated that it may have antidepressant properties, but repeated administration carries serious side-effects such as thrombosis, which limits its usefulness as an antidepressant [4]. ARA290 is described in that work as a peptide that does not have the effects of erythropoietin on blood cells but may still act on brain function [4]. The study was designed to replicate previous findings with a single dose of erythropoietin in healthy volunteers by examining the effects of ARA290 on the cognitive and neural processing of emotions, with the hypothesis that a single dose of ARA290 would lead to a positive shift in information processing compared with placebo at 7 days post-administration [4].
ARA-290 and the innate repair receptor mechanism
The mechanistic account given in the registered research is that brief interaction of ARA 290 with the innate repair receptor produces anti-apoptotic and anti-inflammatory activities in a wide range of cells, tissues and organs, activating repair mechanisms and accelerating healing [2]. This receptor-level description is the basis on which the compound has been taken into the clinical programmes listed above, including the sarcoidosis small fibre neuropathy study [2] and the diabetic macular oedema trial [1]. The mechanistic statements in the evidence are presented as the rationale for those trials rather than as independent clinical findings.
ARA-290 and the separation of repair activity from erythropoiesis
The distinction between ARA 290 and erythropoietin is central to how the research is framed. ARA 290 is described as a non-hematopoietic erythropoietin analogue [3], and in the cognitive study it is described as a peptide that does not have the effects of erythropoietin on blood cells while potentially still acting on brain function [4]. That separation is the stated reason the compound was selected for study in populations where repeated erythropoietin administration would be limited by thrombotic risk [4].
ARA-290 and safety monitoring across the registered trials
Safety monitoring is an explicit component of the registered programmes. In the sarcoidosis study, safety of the treatment was monitored in addition to symptom assessment [2]. In the prediabetes and type 2 diabetes study, safety was monitored by following parameters related to haematology, kidney and liver function and lipid levels [3]. These are protocol-level descriptions of what was measured, not reports of outcomes.
ARA-290 and the regenerative peptide literature
A narrative review of regenerative peptides relevant to chronic pain management has summarised current evidence across a group of compounds that includes collagen peptides, BPC-157, thymosin beta-4, TB-500 and GHK-Cu [5]. That review provides context for where ARA-290 sits within the broader regenerative peptide field, but it is a reference source rather than a primary study of ARA-290 itself [5].
If you are reading this for personal health reasons
ARA-290 is sold by our catalogue strictly for laboratory research use. We do not provide dosing information, medical guidance or recommendations for human use. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] The Use of ARA290 for the Treatment of Diabetic Macular Oedema — ClinicalTrials.gov
- [2] Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis — ClinicalTrials.gov
- [3] ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) — ClinicalTrials.gov
- [4] Cognitive and Neural Effects of ARA290 — ClinicalTrials.gov
- [5] Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. — europe_pmc